home / stock / soltf / soltf short
Short Information | Sosei Co Ltd Ord (OTCMKTS:SOLTF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 36,316 |
Total Actual Volume | 61,021 |
Short Trends | |
---|---|
Cover Days | 5 |
Short Days | 14 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 1,816 |
Average Short Percentage | 74.70% |
Is there a SOLTF Short Squeeze or Breakout about to happen?
See the SOLTF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
10-01-2024 | $8.98 | $9.02 | $9.02 | $8.98 | 300 | 300 | 100% |
08-28-2024 | $10.62 | $10.62 | $10.62 | $10.62 | 200 | 200 | 100% |
08-15-2024 | $9.46 | $9.46 | $9.46 | $9.46 | 100 | 100 | 100% |
08-01-2024 | $9.96 | $10.15 | $10.15 | $9.96 | 500 | 500 | 100% |
05-13-2024 | $9.67 | $9.8 | $9.8 | $9.67 | 1,000 | 900 | 90% |
05-10-2024 | $9.816 | $9.816 | $9.816 | $9.816 | 1 | 1 | 100% |
04-16-2024 | $9.72 | $9.72 | $9.72 | $9.72 | 100 | 100 | 100% |
04-08-2024 | $10.44 | $10.44 | $10.44 | $10.44 | 300 | 300 | 100% |
03-13-2024 | $10.7461 | $10.7461 | $10.7461 | $10.7461 | 465 | 465 | 100% |
03-11-2024 | $11.88 | $13.43 | $13.43 | $11.71 | 50,102 | 30,500 | 60.88% |
02-15-2024 | $8.56 | $8.65 | $8.715 | $8.56 | 1,500 | 100 | 6.67% |
02-14-2024 | $9.5 | $9.5 | $9.5 | $9.5 | 500 | 500 | 100% |
01-29-2024 | $9.81 | $9.822 | $9.822 | $9.75 | 300 | 100 | 33.33% |
01-10-2024 | $10.5 | $10.89 | $10.89 | $10.5 | 2,303 | 200 | 8.68% |
12-15-2023 | $10.2 | $9.95 | $10.2 | $9.95 | 300 | 100 | 33.33% |
12-14-2023 | $10.17 | $10.17 | $10.17 | $10.17 | 1,000 | 1,000 | 100% |
12-04-2023 | $9.708 | $9.48 | $9.708 | $9.48 | 1,100 | 200 | 18.18% |
11-22-2023 | $10 | $10 | $10 | $10 | 500 | 500 | 100% |
10-24-2023 | $9.15 | $9.15 | $9.15 | $9.15 | 100 | 100 | 100% |
10-18-2023 | $9.38 | $9.45 | $9.45 | $9.38 | 350 | 150 | 42.86% |
News, Short Squeeze, Breakout and More Instantly...
Sosei Co Ltd Ord Company Name:
SOLTF Stock Symbol:
OTCMKTS Market:
Dr. Sugita – formerly Vice President, Head of R&D for Bristol Myers Squibb in Japan – brings nearly 20 years’ experience in R&D and commercial roles working within the Japanese businesses of global pharmaceutical companies Tokyo, Japan and Cambridge, UK, ...
QUVIVIQ™ is a potential best-in-class treatment in the high-growth, dual orexin antagonist class of medicines treating sleep disorders, such as insomnia Tokyo, Japan and Cambridge, UK, 1 October 2024 – Nxera Pharma Co., Ltd. (“Nxera” or “the Co...
The approval of QUVIVIQ™, a novel dual orexin receptor antagonist, is based on robust clinical efficacy and safety data, including from a Phase 3 trial in Japan that met all primary and secondary endpoints Plans to make QUVIVIQ available as soon as possible to insomnia patients in Japa...